[Cellular microparticles, potential useful biomarkers in the identification of cerebrovascular accidents]

Med Sci (Paris). 2009 Oct;25(10):843-6. doi: 10.1051/medsci/20092510843.
[Article in French]


The clinical utility of biomarkers depends on their ability to identify high-risk individuals in order to establish preventive, diagnostic or therapeutic measures. Currently, no practical, rapid and sensitive test is available for the diagnosis of acute ischemic stroke. A number of soluble molecules have been identified that are merely associated to these cerebrovascular accidents. Despite this association not a single molecule has the characteristics of a true biomarker directly involved in the pathophysiology of ischemic stroke-none of them is organ-specific and may therefore be elevated in the context of medical comorbidities. When explored as a combination of biomarkers, e.g. matrix metalloproteinase 9, brain natriuretic protein, D-dimer, protein S100B, the question still remains whether serial biomarker analysis provides additional prognostic information. Even S100B, a glial activation protein, has a low specificity for acute ischemic stroke because it may originate from extracranial sources. Current knowledge from the field of cell-derived microparticles suggests that these membrane fragments may represent reliable biomarkers as they are cell-specific and are released early in the pathophysiological cascade of a disease. These microparticles can be found not only in the cerebrospinal fluid but also in tears and circulating blood in case of blood-brain barrier dysfunction. They represent a new challenge in stroke diagnosis and management.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Biomarkers / blood
  • Blood Coagulation
  • Cell-Derived Microparticles / metabolism
  • Fibrinolysis
  • Humans
  • Metalloproteases / blood
  • Stroke / blood*
  • Stroke / diagnosis
  • Stroke / enzymology


  • Biomarkers
  • Metalloproteases